Hepatic Transaminase’s Level in Chronically Treated Diabetic’s Patients (Type 2) at-Alhusain Teaching Hospital in Al- Nasiriyah city

Najim a. Al awwadi1*, Ali B. Roomi2, Makarim Mohammad A, Kefah. Z. Balat3

1Department of Pharmacognasy, College of Pharmacy, Thi-Qar University, Iraq
2General Directorate for Education in Thi-Qar/Iraq
3Department of Pediatric Nursing, College of Nursing, Thi-Qar University, Iraq

*Corresponding author: Najim a. Al awwadi, College of Pharmacy, Thi-Qar University, Iraq. Email: najimabbas@yahoo.fr

Citation: Al awwadi N, Roomi AB, Mohammad MA, Balat KZ (2016) Hepatic Transaminase’s Level In Chronically Treated Diabetic’s patients (Type 2) At Alhusain Teaching Hospital In Al- Nasiriyah city, J Pharma Pharma Sci, 2016: JPPS: 107. DOI:10.29011/2574-7711/100007

Received Date: 26 October, 2016; Accepted Date: 02 December, 2016; Published Date: 08 December, 2016

Abstract

Background: The study was planned to evaluate the liver function of Type 2 Diabetes Mellitus (T2MD) by measuring Serum Glutamic Oxaloacetic Transaminase (SGOT), Serum Glutamic Pyruvic Transaminase (SGPT), plasma glucose, urea and creatinine. The study investigates the level of SGPT and SGOT in patients who suffer from diabetes mellitus at Al-Hussein teaching hospital in Al-nasiriyah city.

Materials and methods: 80 patients who diagnosed as type 2 diabetes mellitus (T2DM) (40 males and 40 females) were included in the study. Forty matched normal individuals were taken as a controlled group. Their age ranged between 40 and 90 years.

Results: In the present study, mean values of SGPT, SGOT, plasma glucose, urea and creatinine were significantly higher in patients than in the controlled group (P<0.01), and this significant deference’s found between the two groups of patients (P <0.01), The mean (± S.D.) SGOT in the controlled group was 25.01±0.77, whereas in T2DM (40-60 years) was 37.87± 3.88 and T2DM (60-90 years) was 53.73 ± 5.05. The mean (± S.D) blood sugar in controlled group was 92.24 ± 2.15, whereas in T2DM (40-60 years) was 246.12 ± 16.23 and 387.00 ± 18.55 in the T2DM (60-90 years). Creatinine levels in controlled group were 0.82 ± 0.35 and in T2DM (40-60 years) was 1.50 ± 0.98 and T2DM (60-90 years) was 2.03 ± 1.10. There was a significant increase in the SGPT, SGOT, plasma glucose, urea and creatinine in T2DM (60-90 years) compared with T2DM (40-60 years).

Conclusion: The values of the liver function tests in patients with T2DM were significantly higher than that of controlled patients. Moreover, patients had higher glucose, urea and creatinine than in the controlled group.

Keywords: Diabetes Mellitus; SGPT; SGOT; Glucose; Urea; Creatinine

Introduction

Type 2 diabetes mellitus is the most common type represents (90%) of DM patients worldwide. Type 2DM can be characterized by insulin resistance or reduced insulin sensitivity (down regulation of Insulin receptors). Type-2 DM is also most commonly associated with obesity in middle-aged individuals. There is an association between diabetes and liver injury. In hyperglycemias states, there will be an intracellular glycogen accumulation in the hepatocytes due to increased glycogen synthesis, causing typical biochemical findings of mild to moderately elevated amino transferases, normal liver synthetic function, with or without mild elevations of alkaline...
phosphates. The prevalence of Type 2 Diabetes Mellitus (T2DM) is higher in patients who have suffered from certain liver diseases. Therefore, it is speculated that there is a pathogenic link between liver disease progression and T2DM.

AST (SGOT) and ALT (SGPT) are sensitive indicators of liver damage from different types of disease. But it must be emphasized that higher-than-normal levels of these liver enzymes should not be automatically equated with liver disease. They may mean liver problems or they may not. The interpretation of elevated AST and ALT levels depends upon the whole clinical picture and so it is best done by doctors experienced in evaluating liver disease.

At the other side idiosyncratic hepatotoxicity is a rare and unpredictable event of liver injury affecting generally less than 1 in 10,000 patients treated with certain drugs. However, it is a serious clinical problem as it accounts for 10% of all drug-induced liver failure cases. Since idiosyncratic drug reactions are not detected in preclinical testing and in most cases not even during clinical trials, the problem surfaces generally after the drug is approved and hundreds of thousands of patients are being treated. Idiosyncratic hepatotoxicities are currently the main cause of Food and Drug Administration-mandated warnings, restrictions of use or even withdrawals of drugs from the market. As such, this is a considerable problem for the pharmaceutical industry and for regulatory agencies worldwide.

And certain medicinal agents, when taken in overdoses and sometimes even when introduced within therapeutic ranges, may injure the organ. The list of hepatotoxic drugs is huge and a complete coverage is difficult. To sum up thus there is a large category of drugs used for different therapeutic indications which are toxic to the liver and thus should be cautiously administered. One of the recent examples of drugs causing idiosyncratic hepatotoxicity and liver failure was the anti diabetic drugs.

Metformin is the first choice oral anti diabetic drug for type 2 diabetes and currently the most consumed metformin-induced hepatotoxicity but rarely. Fewer than 10 cases have been reported. However, given the increasing prevalence of type 2 diabetes and expanding indications for metformin, are found that the clinical and laboratory findings of metformin-induced hepatotoxicity and MALA (Metformin-Associated Metabolic Acidosis) in the older diabetic patients. It is important that clinicians be alert to the occurrence of rare but potentially serious side effects of this drug, such as idiosyncratic hepatotoxicity [1]. Troglitazone was an effective anti diabetic drug with a fundamentally new mechanism of action. However, within a year after its widespread use, individual cases of liver injury and failure were reported. If the injury does not progress, the model may explain the fact that about 2% of patients treated with troglitazone but only 0.6% of patients receiving placebo experienced a significant increase of plasma ALT activities.

So increased activities of liver enzymes such as Aspartame Aminotransferase (AST), Alanine Aminotransferase (ALT) and γ-Glutamyltranspeptidase (GGT) are indicators of hepatocellular injury and associated with insulin resistance. Liver pathology among diabetics is similar to that of alcoholic liver disease, including fatty liver (steatosis), steatohepatitis, fibrosis, and cirrhosis. The elevated serum activity of the two aminotransferases, aspartate aminotransferase (AST) and Alanine Aminotransferase (ALT), is the most frequently measured indicators of metabolic liver disease and occurs in chronically treated old diabetics patients more frequently than in the general population due to endogenous antioxidant deficiencies may uncover potential liabilities of drugs even at therapeutic levels, which could provide a strong indication for possible idiosyncratic reactions in humans.

Materials and Methods

Design of study

The study, conducted at Al-Hussein teaching hospital in Al-Nasiriayah city during 6 months (from 20th of October 2012 to 28th of March 2013). Our study samples were (80) patients selected between the ages of 18 to 90 years.

Collection of Blood Sample

10 ml of venous blood sample was collected from each fasting type 2DM and controlled group patients and allowed to clot and to get the serum by putting it in an empty disposable tube which is then separated in the centrifuge at 3000 (rpm) for 10 minutes, the serum samples were separated, stored at (-20°C) for later measurement biochemical parameters, unless used immediately. The clinical chart of this study describes experimental parameters in the following Table: 1

| Name:- | |
|---------|---------|
| Sex:-   |         |
| Age:-   |         |
| Address:-|        |
| Occupation:- | |
| Marital status:- | |
| History of disease:- | |
| Type of investigation:- | |
| Type of treatment:- | |
| Biochemical parameters | |
| Serum glucose | |
Liver function test:
- serum glutamic oxaloacetic transaminase (sgot)
- serum glutamic pyruvic transaminase (sgpt)

Renal function test:
- urea test
- creatinine test

Biochemical Parameters

The used reagents were supplied by Biolabo (France), and Serum glucose was measured according to. (SGOT) and (SGPT) were measured according to [2]. Determination of plasma creatinine was carried out using Jaffe’s method described by [3]. Urea was estimated using urease-Berthelot’s method described by [4].

Statistical Analysis

Statistical analysis was done by using the software SPSS version 17.0: the results were expressed as mean ± standard deviations (Mean ± SD). One way ANOVA-test was used to compare parameters in different studied groups. P-values (P < 0.01) were considered statistically significant.

Results

| Parameters | Control (n=40) | T2DM (40-60 years) | T2DM (60-90 years) |
|------------|---------------|-------------------|-------------------|
| SGPT (U/L) | 18.00 ± 1.12  | 38.20 ± 4.03 b     | 54.88 ± 5.88 a     |
| SGOT (U/L) | 25.01 ± 0.77  | 37.87 ± 3.88 b     | 53.73 ± 5.05 a     |
| Glucose (mg/dl) | 92.24 ± 2.15 c | 246.12 ± 16.23 b   | 387.00 ± 18.55 a   |
| Urea (mg/dl) | 20.50 ± 0.82  | 29.21 ± 3.25 b     | 33.83 ± 3.89 a     |
| Creatinine (mg/dl) | 0.82 ± 0.35 c | 1.50 ± 0.98 b      | 2.03 ± 1.10 a     |

* Note: Each value represents (mean ± SD) values with non identical superscript (a, b or c …Extra.) were considered significantly different (P < 0.01).

Table 2: Mean values of the biochemical parameters in T2MD and the control group.

![Figure 1: Mean values of the biochemical parameters in T2MD and the controlled group.](chart)

Figure 1: Mean values of the biochemical parameters in T2MD and the controlled group.

In the current study, SGPT, SGOT, plasma glucose, urea and creatinine were estimated in type 2 diabetic patients and controlled group (Table 2) and (Figure 1). The mean (± S.D.) SGPT in the controlled group was 18.00± 1.12, whereas in T2DM (40-60 years) was 38.20 ± 4.03 and T2DM inpatients aged between (60-90 years) was 54.88 ± 5.88. The mean (± S.D.) SGOT in the controlled group was 25.01±0.77, while in T2DM aged (40-60 years) was 37.87± 3.88 and T2DM (60-90 years) was 53.73 ± 5.05. The mean (± S.D.) blood sugar in the controlled group was 92.24 ± 2.15, whereas in T2DM (40-60 years) was 246.12 ± 16.23. The mean (±S.D.) and T2DM (60-90 years) was 387.00 ± 18.55. Urea levels in controlled group were 20.50 ± 0.99 and in T2DM (40-60 years) were 29.21 ± 3.25 and T2DM (60-90 years) were 33.83 ± 3.89. Creatinine levels in the controlled patients were 0.82 ± 0.35 and in T2DM (60-90 years) were 1.50 ± 0.98 and T2DM (60-90 years) were 2.03 ± 1.10. There was a significant increase in the SGPT, SGOT, plasma glucose, urea and creatinine in T2DM (60-90 years) compared with T2DM (40-60 years) (P < 0.01).

Discussion

The findings in our study are similar to those of [5] who reported that the elevated serum activity of the SGPT and SGOT, are the most frequently measured indicators of liver disease and occurs in diabetics more frequently than in the general population. Our study also supported the finding of important study conducted by [6]. He tried to assess the prevalence of abnormal liver function tests in patients with diabetes mellitus, and all these studies are coming with agreement with who pointed out that the mean values of SGPT and SGOT were significantly higher in diabetic patients than in the controlled patients (P<0.01).

Our results also indicated another logic cause of transaminase enzymes elevation to improve the results of which pointed out that a serious clinical hepatotoxicity problem as it accounts for 10% of all drug-induced liver failure cases which were characterized by elevation of SGOT and SGPT level. So, when certain drugs taken in over doses or within therapeutic doses may induce hepatic injury [7]. Liver pathology among diabetics is similar to that of alcoholic liver disease, including fatty liver (steatosis), steatohepatitis, fibrosis, and cirrhosis.

Actual study improve also in additional to the dose - toxicity relationship or effect there are age effect demonstrated in the table 2 of our study which showed the category of patients age (60-90 years) have significant a highest level of SGOT, SGPT than in the patient aged (40-60), this significant defenses between the ages has been shown in the other parameters included in our study.

Plasma creatinine and urea are established markers of Glomerular Filtration Rate (GFR). Though plasma creatinine is more sensitive index of kidney function than the plasma urea level. This is because creatinine fulfills most of the requirements for a perfect filtration marker. This observation is similar to the reports of and
In their report submitted that raised plasma creatinine and urea levels in diabetic patient may indicate a pre-renal problem such as volume depletion [8]. In his submission suggested that high creatinine in diabetic patient may be due to nephrons impairment [9].

**Conclusion**

The values of liver function tests in patients with type 2 diabetes mellitus were significantly higher than that of controlled patients. Moreover, patients had higher glucose, urea and creatinine in comparison to the controlled group. Accordingly, assessment of liver function tests is highly recommended for diabetic patients. Additionally, further studies on the liver function of diabetic patients need to be done as well.

**References**

1. Rhee MK, Herrickm K, Ziener DC (2010) Many Americans have pre-diabetes and should be considered for metformin therapy. Diabetes Care 33: 49-54.
2. Reitman S, Frankel S (1957) Amer. J. Clin. Path 28: 56.
3. Bowers LD, ET Wong (1980) Kinetic serum creatinine assays critical evaluation and review. Clin. Chem 26: 555-561.
4. Richterich R, H Kuffer (1973) the determination of urea in plasma and serum by a urease/Berthelot method, adapted to the Greiner Electronic Selective Analyzer GSA. Z. Klin. Chem. Klin. Biochem 11: 553-564.
5. Everhart JE (1995) Diabetes in America. 2nd ed. National Institute of Health. National Institute of Diabetes and Kidney Diseases. Washington, DC: GPO 457-483.
6. Gonem S, Wall A, De P (2007) Prevalence of abnormal liver function tests in patients with diabetes mellitus, Endocrine Abstracts 13: 157.
7. Aashish P, Tarun S, Pallavi B (2012) Drug-Induced Hepatotoxicity. Journal of Applied Pharmaceutical Science 2: 233-243.
8. Alder AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, et al. (2003) Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 63: 225-232.
9. Judykay T (2007) Nutrition for reducing urea and creatinine in the blood. Diabetes Care 27: 2191-2192.
10. Wagle TJ (2010) Gender wise comparison of serum creatinine and blood sugar levels in type 2 diabetic patients. Bombay Hospital J 52: 64-68.
11. Ayman SI, Hammad Mekky KE, Elsonni Abdalla BE, Ali KA (2011) Liver function tests in type 2 Sudanese diabetic patients 3: 17-21.
12. Chatlla R, West AB (1996) Hepatomegaly and abnormal liver tests due to glycogenosis in adults with diabetes. Medicine (Baltimore) 75: 327-333.
13. Cone CJ, Bachyrucz AM, Muruta GH (2010) Hepatotoxicity associated with metformin therapy in treatment of type 2 diabetes mellitus with nonalcoholic fatty liver disease. Ann Pharmacother 1455-1659.
14. Elizabeth H (2005) Elevated Liver Function Tests In Type 2 Diabetes 25: 330-360.
15. Erbey JR, Silberman C, Lydick E (2000) Prevalence of abnormal serum alanine aminotransferase levels in obese patients and patients with type 2 diabetes. Am J Med 109: 588-590.
16. Erbey JR, Silberman C, Lydick E (2000) Prevalence of abnormal serum alanine aminotransferase levels in obese patients and patients with type 2 diabetes. Am J Med 109: 588-590.
17. Ersin Aksay (2007) Turk J Med Sci 37: 173-175.
18. Graham DJ, Green L, Senior JR, Nourjah P (2003) Troglitazone-induced liver failure: A case study. Am. J. Med 114: 299-306.
19. Greiling H, Gressner AM, Lehrbuch D, Klinischen (1995) Chemie und Pathobiochemie , 3rd , Stuttgart/ New York Schattauer Verlag.
20. Kaplowitz N (2005) idiosyncratic drug hepatotoxicity. Nature Reviews Drug Discovery 4: 489-499.
21. Marchesini G, Brzi M, Bianchi G, Tomassetti S, Bugianses E, et al. (2001) Nonalcoholic fatty liver disease. A feature of metabolic syndrome. Diabetes 50: 1844-1850.
22. Ong MM, Latchoumycandane C, Boelsterli UA (2007) Troglitazone-induced hepatic necrosis in an animal model of silent genetic mitochondrial abnormalities. Toxicol Sci 97: 205-213.
23. Perrone RD, Madias NE, Levey AS (1992) Serum creatinine as index of renal function: new insights into old concepts. Clin Chem 38: 1933-1953.
24. Po-Shiuan Hsieh, Yen-Ju Hsieh (2011) Impact of liver diseases on the development of type 2 diabetes mellitus. World J Gastroenterol 17: 5240-5245.
25. Rubino F, Gagner M (2002) Potential of surgery for curing type 2 diabetes mellitus. Ann. Surg 236: 554-559.
26. Watanabe I, Tomita A, Shimizu M, Sugawara M, Yasumo H, et al. (2003) A study to survey susceptible genetic factors responsible for troglitazone-associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus. Clin. Pharmacol. Ther. 73: 435-445.
27. Watkins PB (2005) idiosyncratic liver injury: Challenges and approaches. Toxicol Pathol 33: 1-5.